Analyst Coverage
| Analyst |
Firm |
Contact Information |
| George B. Zavoico, PhD |
Cantor Fitzgerald & Co
|
Phone: 212-829-4758
|
| Y. Katherine Xu, Ph.D. |
Credit Suisse
|
Phone: 212-538-7097
|
| Pat Moriarty, Ph.D. |
Fortis Securities LLC
|
Phone: 212-340-5497
|
| Matthew Osborne |
Lazard Capital Markets
|
Phone: 212-632-1499
|
| Howard Liang |
Leerink Swann
|
Phone: 617-918-4857
|
| Bret Holley, Ph.D. |
Oppenheimer
|
Phone: 212-667-7289
|
| Gregory Wade |
Pacific Growth Equities
|
Phone: 415-274-6863
|
| Simos Simeonidis, Ph.D. |
Rodman & Renshaw
|
Phone: 212-430-1790
|
Poniard Pharmaceuticals is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Poniard Pharmaceuticals's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Poniard Pharmaceuticals or its management. Poniard Pharmaceuticals does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
Stock Information
PARD - (NASD)
$2.52
- 0.37
|
Nov 21, 2008
4:00 PM ET |
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
